Published in Medical Letter on the CDC and FDA, November 28th, 2004
"Our first IND for NX 473 represents a significant step toward our goal to develop and commercialize a diverse pipeline of oncology products," said Jerry McMahon, PhD, chairman and chief executive officer of NeoRx. "Our plan is to initiate the lung cancer Phase II trial in the first half of 2005, followed by a pilot study with NX 473 for the treatment of colorectal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA